SGLT2 inhibitors were found to confer both cardiovascular and renal protection; clinical trials have demonstrated that SGLT2 inhibitor treatment results in a 30–40% relative risk reduction of cardiovascular death and hospitalization, which was mainly driven by reduction of heart failure [51,52,53]. The gene discussed is SLC5A2; the disease is heart failure.